Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	60.29M
Revenue (ttm)	n/a
Net Income (ttm)	-25.45M
Shares Out	36.49M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,809
Open	1.6
Previous Close	1.65
Day's Range	1.6 - 1.68
52-Week Range	1.09 - 4.7
Beta	-0.31
Analysts	Buy
Price Target	7.14 (+338.0%)
Earnings Date	Nov 14, 2022

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing Nu...

• Industry: Biotechnology
• Founded: 2000
• CEO: Chaim Lebovits
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: BCLI

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BCLI stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 338.04% from the latest price.

Price Target

$7.14

(338.04% upside)

Analyst Consensus: Buy

Stock Forecasts